Adalimumab-Afzb Injection shortage
Adalimumab-Afzb Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 25, 2026.
Pfizer is stopping production of Adalimumab-Afzb Injection, and this change may be permanent. Pfizer does list Abrilada (kit) as a related product that may be available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Adalimumab-Afzb Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 9, 2025Currently in shortage1 of 1 product affected.
-
Oct 9, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Pfizer Inc. 📞 800-646-4398 1 NDC click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Abrilada, Injection, Kit (NDC 0025-0325-01) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Adalimumab-Afzb Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Adalimumab-Afzb Injection? options further down this page.
Why is Adalimumab-Afzb Injection in shortage?
Pfizer has reported to the FDA that they are permanently stopping the manufacture of Adalimumab-Afzb (sold under the brand name Abrilada) in the injection kit form (NDC 0025-0325-01). That's why this product is listed on the FDA shortage list as "to be discontinued."
Pfizer did not share a more specific public reason for why they made this decision — just that they are discontinuing the manufacture of this drug. It's worth knowing that this report reflects only Pfizer's version of this product, so it speaks only to their Abrilada kit and not to any other manufacturer's adalimumab products.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Adalimumab-Afzb Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Adalimumab-Afzb Injection?
Adalimumab-Afzb (the brand Abrilada) is currently on the FDA shortage list. The record shows this product is being discontinued by the manufacturer that filed the report, so this supply problem may be a permanent change rather than a temporary gap.
The only company on this record, Pfizer Inc., lists Abrilada in the injection kit form (NDC 0025-0325-01) as being discontinued. No separate strengths are reported on this record, so there is no other strength here that still has supply to point you toward. The reason given is simply that the manufacturer is stopping production of this drug.
Because this is a discontinuation, the most important next step is a conversation with your prescriber. Please do not stop, skip, or change your dose on your own.
Here is how I'd suggest handling it:
- Talk with your prescriber or pharmacist soon about your plan, since this product is being discontinued.
- Ask your pharmacy whether the same medicine, Abrilada, can still be sourced from Pfizer Laboratories — it may not be in local stock, but they can check.
- If it cannot be found, ask your prescriber about a clinician-chosen alternative that fits your needs.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Adalimumab-Afzb Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Adalimumab-Afzb Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Abrilada | Kit | Pfizer Laboratories Div Pfizer Inc | 00025-0325-02 |
Therapeutic equivalents & pricing 5 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Abrilada | Pfizer | 1 kit | — | — | FDA listed |
| Abrilada | A-S | 2 kits | — | — | FDA listed |
| Abrilada | Pfizer | 2 kits | — | — | FDA listed |
| Abrilada | Pfizer | 2 kits | — | — | FDA listed |
| Abrilada | A-S | 1 kit | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Adalimumab-Afzb Injection — that fall in the same broad treatment class (anti-inflammatory tumor necrosis factor inhibitor) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other rheumatology shortages
Adalimumab-Afzb Injection shortage FAQs
Is Adalimumab-Afzb Injection in shortage?
Which products are affected?
When will Adalimumab-Afzb Injection be available again?
Can I still get Adalimumab-Afzb somewhere?
What should I do if I take Adalimumab-Afzb Injection?
Still have a question about the Adalimumab-Afzb Injection shortage?
Ask a pharmacist about this shortage →View Adalimumab-Afzb Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.